Could a common heart drug stop high blood pressure before it starts?
NCT ID NCT07727252
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial tests whether eplerenone, a drug that blocks the hormone aldosterone, can prevent the onset of high blood pressure in people aged 30–55 who have a mild, early form of primary aldosteronism but normal blood pressure. Participants will receive either eplerenone or a placebo for up to 5 years. The goal is to see if early treatment can protect the heart and kidneys and reduce the need for future blood pressure medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eplerenone, a mineralocorticoid receptor antagonist
- What this could lead to
- If successful, this could establish a new strategy to prevent hypertension and heart/kidney damage in people with subclinical primary aldosteronism, potentially changing international treatment guidelines.
- What could go wrong
- This is an early-to-mid-stage trial, and the condition is not widely recognized. Risks include hyperkalemia, kidney injury, and low blood pressure. Results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBCLINICAL PRIMARY ALDOSTERONISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.